Journal
CANCER LETTERS
Volume 452, Issue -, Pages 51-58Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2019.03.018
Keywords
Macrophages; Dendritic cells; Phagocytosis; Antitumer immunity
Categories
Funding
- National Research Foundation of Korea (NRF) - Korea government (MSIT) [2017R1A3B1023418]
- Basic Science Research Program through the National Research Foundation of Korea (NRF) - Korea government (MSIT) [2017R1A2B4002662]
- KU-KIST Graduate School of Converging Science and Technology Program
- KIST Institutional Program
- National Research Foundation of Korea [2017R1A2B4002662, 2017R1A3B1023418] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Myeloid lineage immune cells, such as macrophages and dendritic cells, play important roles in the induction of antitumor immunity during the initial stage of the cancer-immunity cycle, eliciting antitumor adaptive immunity by phagocytosing cancer cells and processing cancer-specific antigens, and then presenting these antigens to T cells. During this process, cancer cell phagocytosis can be prevented by inhibitory signals, and the signaling cascades that elicit immune responses against cancer antigens can be inhibited by immunosuppressive myeloid cells in the tumor microenvironment. A number of therapeutic strategies for enhancing cancer cell phagocytosis and promoting antitumor immunity by targeting myeloid lineage cells have recently been developed. Here, we discuss recent advances in cancer immunotherapy that involve the targeting of myeloid lineage immune cells to induce effective antitumor immunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available